Labeling Type
HUMAN PRESCRIPTION DRUG LABEL
Status
Approved
Full Title
These highlights do not include all the information needed to use OSVYRTI safely and effectively. See full prescribing information for OSVYRTI. OSVYRTI (denosumab-desu) injection, for subcutaneous use Initial U.S. Approval: 2025 OSVYRTI (denosumab-desu) is biosimilar to PROLIA (denosumab).
United States
Data Sources & Disclaimer: Approval information is sourced from official FDA databases. This content is for informational purposes only and does not constitute medical or regulatory advice. Always refer to official FDA websites for the most current information.
